LUXTURNA
Biological
Spark Therapeutics, Inc.
Total Payments
$16.0M
Transactions
2,150
Doctors
927
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $964,848 | 113 | 18 |
| 2023 | $2.1M | 119 | 13 |
| 2022 | $2.2M | 224 | 112 |
| 2021 | $2.5M | 243 | 132 |
| 2020 | $1.9M | 141 | 54 |
| 2019 | $4.6M | 820 | 496 |
| 2018 | $1.8M | 490 | 231 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $8.2M | 49 | 51.3% |
| Unspecified | $6.7M | 518 | 41.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $584,477 | 137 | 3.7% |
| Consulting Fee | $350,371 | 66 | 2.2% |
| Travel and Lodging | $83,427 | 194 | 0.5% |
| Food and Beverage | $65,227 | 1,165 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $12,200 | 7 | 0.1% |
| Education | $2,606 | 14 | 0.0% |
Payments by Type
General
$9.3M
1,632 transactions
Research
$6.7M
518 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WHO RECEIVED AN ADENOVIRUS-ASSOCIATED VIRAL VECTOR SEROTYPE 2 CONTAINING THE HUMAN RPE65 GENE (AAV2-HRPE65V2, VORETIGENE NEPARVOVEC-RZYL) ADMINISTERED VIA SUBRETINAL INJECTION | Spark Therapeutics, Inc. | $4.4M | 0 |
| A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGENE NEPARVOVEC | Spark Therapeutics, Inc. | $766,573 | 0 |
| A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene AAV2-hRPE65v2, Voretigene Neparvovec-rzyl Administered Via Subretinal Injection | Spark Therapeutics, Inc. | $541,093 | 0 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WHO RECEIVED AN ADENOVIRUS-ASSOCIATED VIRAL VECTOR SEROTYPE 2 CONTAINING THE HUMAN RPE65 GENE AAV2-HRPE65V2, VORETIGENE NEPARVOVEC-RZYL ADMINISTERED VIA SUBRETINAL INJECTION | Spark Therapeutics, Inc. | $228,643 | 0 |
| A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection | Spark Therapeutics, Inc. | $218,099 | 0 |
| A SAFETY AND EFFICACY STUDY IN SUBJECTS WITH LEBER CONGENITAL AMAUROSIS LCA USING ADENO-ASSOCIATED VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN RPE65 TO THE RETINAL PIGMENT EPITHELIUM RPE AAV2-HRPE65V2-301 | Spark Therapeutics, Inc. | $148,150 | 0 |
| AAV2-HRPE65V2-102; AAV2-HRPE65V2-301; AAV2-HRPE65V2-LTFU-01 | Spark Therapeutics, Inc. | $132,893 | 0 |
| CHOP PENN PSA | Spark Therapeutics, Inc. | $76,442 | 0 |
| AAV2-hRPE65v2-102; AAV2-hRPE65v2-301; AAV2-hRPE65v2-LTFU-01 | Spark Therapeutics, Inc. | $38,865 | 0 |
| A FOLLOW-ON STUDY TO EVALUATE THE SAFETY OF RE-ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTOR CONTAINING THE GENE FOR HUMAN RPE65 AAV2-HRPE65V2 TO THE CONTRALATERAL EYE IN SUBJECTS WITH LEBER CONGENITAL AMAUROSIS LCA PREVIOUSLY ENROLLED IN A PHASE 1 STUDY | Spark Therapeutics, Inc. | $36,773 | 0 |
| A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec | Spark Therapeutics, Inc. | $10,030 | 0 |
| A SAFETY AND EFFICACY STUDY IN SUBJECTS WITH LEBER CONGENITAL AMAUROSIS (LCA) USING ADENO-ASSOCIATED VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN RPE65 TO THE RETINAL PIGMENT EPITHELIUM (RPE) [AAV2-HRPE65V2-301] | Spark Therapeutics, Inc. | $3,800 | 0 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WITH SEVER HEMOPHILIA B WHO RECEIVED ADENO-ASSOCIATED VIRAL VECTORS EXPRESSING HUMAN FACTOR IX | Spark Therapeutics, Inc. | $80.60 | 0 |
Top Doctors Receiving Payments for LUXTURNA — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , OD | Optometrist | Portland, OR | $125.00 | 1 |
| , M.D | Ophthalmology | Lombard, IL | $125.00 | 1 |
| , M.D | Ophthalmology | New York, NY | $125.00 | 1 |
| , OD, FAAO | Optometrist | New York, NY | $125.00 | 1 |
| , MD | Ophthalmology | New York, NY | $125.00 | 1 |
| , MD | Ophthalmology | New York, NY | $125.00 | 1 |
| , MD | Ophthalmology | New York, NY | $125.00 | 1 |
| , M.D | Retina Specialist | New York, NY | $125.00 | 1 |
| , O.D | Pediatrics | Forest Grove, OR | $125.00 | 1 |
| , O.D | Low Vision Rehabilitation | New York, NY | $125.00 | 1 |
| , O.D | Corneal and Contact Management | Forest Grove, OR | $125.00 | 1 |
| , M.D | Ophthalmology | New York, NY | $125.00 | 1 |
| , OD | Optometrist | Iselin, NJ | $125.00 | 1 |
| , M.D | Ophthalmology | Brooklyn, NY | $125.00 | 1 |
| Avnish Deobhakta | Retina Specialist | Boston, MA | $125.00 | 1 |
| , O.D | Optometrist | Wilsonville, OR | $125.00 | 1 |
| , MD | Surgery | Hinsdale, IL | $125.00 | 1 |
| , OD | Optometrist | New York, NY | $125.00 | 1 |
| , O.D | Optometrist | Portland, OR | $125.00 | 1 |
| , M.D | Ophthalmology | Cleveland, OH | $125.00 | 1 |
| , M.D | Ophthalmology | New York, NY | $125.00 | 1 |
| , M.D | Ophthalmology | New York, NY | $125.00 | 1 |
| Everett Madson | — | Omaha, NE | $124.99 | 1 |
| , M.D | Ophthalmology | Scranton, PA | $124.99 | 1 |
| , MD | Ophthalmology | Wilkes Barre, PA | $124.99 | 1 |
Ad
Manufacturing Companies
- Spark Therapeutics, Inc. $15.9M
- Novartis Pharma AG $87,948
Product Information
- Type Biological
- Total Payments $16.0M
- Total Doctors 927
- Transactions 2,150
About LUXTURNA
LUXTURNA is a biological associated with $16.0M in payments to 927 healthcare providers, recorded across 2,150 transactions in the CMS Open Payments database. The primary manufacturer is Spark Therapeutics, Inc..
Payment data is available from 2018 to 2024. In 2024, $964,848 was paid across 113 transactions to 18 doctors.
The most common payment nature for LUXTURNA is "Royalty or License" ($8.2M, 51.3% of total).
LUXTURNA is associated with 13 research studies, including "A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WHO RECEIVED AN ADENOVIRUS-ASSOCIATED VIRAL VECTOR SEROTYPE 2 CONTAINING THE HUMAN RPE65 GENE (AAV2-HRPE65V2, VORETIGENE NEPARVOVEC-RZYL) ADMINISTERED VIA SUBRETINAL INJECTION" ($4.4M).